Indiana Trust & Investment Management CO lessened its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 7.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,874 shares of the medical research company’s stock after selling 318 shares during the period. Indiana Trust & Investment Management CO’s holdings in Amgen were worth $803,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Kwmg LLC bought a new stake in Amgen in the second quarter valued at approximately $108,000. Mainstay Capital Management LLC ADV bought a new stake in Amgen in the second quarter valued at approximately $111,000. Braun Bostich & Associates Inc. bought a new stake in Amgen in the first quarter valued at approximately $113,000. WealthTrust Fairport LLC bought a new stake in Amgen in the first quarter valued at approximately $121,000. Finally, Gables Capital Management Inc. bought a new stake in Amgen in the first quarter valued at approximately $174,000. Institutional investors and hedge funds own 82.48% of the company’s stock.

AMGN has been the topic of several research analyst reports. Cann restated a “buy” rating and issued a $224.00 price objective on shares of Amgen in a research note on Monday, July 30th. Oppenheimer restated a “buy” rating and issued a $224.00 price objective on shares of Amgen in a research note on Tuesday, August 28th. Mizuho restated a “buy” rating and issued a $200.00 price objective on shares of Amgen in a research note on Friday, July 27th. Goldman Sachs Group restated a “buy” rating and issued a $228.00 price objective on shares of Amgen in a research note on Friday, July 27th. Finally, Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $234.00 price objective on the stock in a research note on Monday, October 1st. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $204.90.

Shares of NASDAQ AMGN opened at $197.39 on Friday. The company has a market cap of $134.17 billion, a PE ratio of 15.69, a PEG ratio of 2.02 and a beta of 1.40. The company has a debt-to-equity ratio of 2.03, a quick ratio of 3.12 and a current ratio of 3.39. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $210.19.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.52 by $0.31. The company had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the company earned $3.27 earnings per share. Equities research analysts predict that Amgen, Inc. will post 13.96 earnings per share for the current year.

In other news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $195.71, for a total transaction of $298,457.75. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.27% of the stock is currently owned by company insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Story: What Does Beta Mean In Stock Selection

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.